Patel S, Stone M D, Coupland C, Hosking D J
Metabolic Unit, Queens Medical Centre, Nottingham, England.
J Bone Miner Res. 1993 Dec;8(12):1467-73. doi: 10.1002/jbmr.5650081209.
Bisphosphonates are a safe and effective treatment for Paget's disease of bone, but little information is available about the factors influencing the duration of remission so obtained. We assessed 60 patients with Paget's disease treated with disodium pamidronate (APD). The mean duration of remission was 9.5 months (range 3-25). The major influences were the initial pretreatment alkaline phosphatase (ALP; r = -4.6, p < 0.0001), minimum posttreatment ALP (r = -0.51, p < 0.0001), and the rate of response of bone turnover to the first dose of APD (r = 0.61, p < 0.0001). Multiple linear regression showed that the initial response to treatment was the most significant influence. Also, despite a minimum ALP within the normal range, the duration of remission varied considerably (4-25 months). This may be due to the difficulties in applying a population-based normal range to individuals.
双膦酸盐是治疗佩吉特骨病的一种安全有效的药物,但关于影响由此获得的缓解期持续时间的因素,目前所知甚少。我们评估了60例接受帕米膦酸二钠(APD)治疗的佩吉特骨病患者。缓解期的平均持续时间为9.5个月(范围3 - 25个月)。主要影响因素为初始治疗前碱性磷酸酶(ALP;r = -4.6,p < 0.0001)、治疗后最低ALP(r = -0.51,p < 0.0001)以及骨转换对首剂APD的反应率(r = 0.61,p < 0.0001)。多元线性回归显示,治疗的初始反应是最显著的影响因素。此外,尽管最低ALP在正常范围内,但缓解期持续时间差异很大(4 - 25个月)。这可能是由于将基于人群的正常范围应用于个体存在困难。